Michael Plundo, DO
Family Medicine · Greensburg, PANPI 1932366945
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $125,413 of the $151,485 with a category attached, or 82.8%. 60 manufacturers reported payments, led by Novo Nordisk at 53.3% of the total. Reporting peaked in 2020 at $36,259 and has fallen 56.7% since, to $15,703 in 2025. Among family medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,213 payments — averaging $124.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$81K
- AstraZeneca$35K
- Johnson & Johnson$24K
- AbbVie$2K
- Lilly USA, LLC$1K
- Amgen$895
- plus $7K from 54 others
What the payments were for
- Consulting fees$1000%
- Speaking & faculty fees$125,41383%
- Travel & lodging$4,6113%
- Food & beverage$21,28514%
- Education$760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$42,968
- Ozempic$33,375
- FARXIGA$32,057
- XARELTO$13,884
- INVOKANA$8,994
- BREZTRI$821
- BEVESPI AEROSPHERE$693
- AIRSUPRA$290
- V-GO$228
- BREZTRI AEROSPHERE$151
- SYMBICORT$151
- FASENRA$151
- NURTEC ODT$125
- Repatha$123
- Oncology$118
- AFREZZA$116
- PROCLAIM$112
- CALQUENCE$111
- ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH$106
- ANDEXXA$103
How this compares
$151,485 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 153 | $173,791 |
| FarxigaDapagliflozin Propanediol | 166 | $120,848 |
| XareltoRivaroxaban | 134 | $108,299 |
| JardianceEmpagliflozin | 79 | $90,662 |
| EliquisApixaban | 98 | $84,020 |
| RybelsusSemaglutide | 53 | $62,359 |
| TrulicityDulaglutide | 35 | $31,882 |
| JanuviaSitagliptin Phosphate | 42 | $30,398 |
| Xigduo XrDapaglifloz Propaned/Metformin | 36 | $29,499 |
| TradjentaLinagliptin | 44 | $28,547 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $25,175 |
| MounjaroTirzepatide | 23 | $23,256 |
| MyrbetriqMirabegron | 22 | $20,583 |
| V-Go 20Sub-Q Insulin Device, 20 Unit | 30 | $19,053 |
| Repatha SureclickEvolocumab | 18 | $14,361 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $80,758 | $236,150206 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Synjardy Xr | $249 | $136,659153 claims |
| AstraZenecaFarxiga, Brilinta | $34,603 | $126,177178 claims |
| Johnson & JohnsonXarelto, Invokana | $24,466 | $120,178149 claims |
| PfizerEliquis, Paxlovid | $515 | $86,879114 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Anoro Ellipta | $365 | $60,882148 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,010 | $58,11275 claims |
| MerckJanuvia, Lagevrio (Eua) | $236 | $36,75865 claims |
| Astellas Pharma US IncMyrbetriq | $90 | $20,58322 claims |
| AbbVieSynthroid | $2,488 | $5,005106 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Greensburg
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Nathan BennettPittsburgh$465K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
- H WilkinsSellersville$380K
- Deborah WittPhiladelphia$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.